GlassScriptPhysician profile
Peter Matthew Sylves
NPI 1952350407
$7,064.32
in general payments reported to CMS, 2019-2025
41 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $500 · 2021: $602 · 2022: $806 · 2023: $1,050 · 2024: $1,474 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,834.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,134.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $841.20 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $754.94 | 2021-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $449.37 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.67 | 2019-2025 | Jardiance |
| Amgen INC. | $355.20 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $323.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $284.79 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $264.71 | 2019-2025 | |
| Exact Sciences Corporation | $212.05 | 2023-2025 | Cologuard Collection Kit |
| Grifols USA, LLC | $198.03 | 2019-2025 | Prolastin-C Liquid |
| Astellas Pharma US INC | $180.16 | 2019-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.62 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $156.49 | 2019-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $150.46 | 2019-2025 | Zoryve |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Sylves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.